ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis

Company Overview

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $14.80 to $16.23
• 50-Day Range: $12.10 to $15.91
• 52-Week Range: $7.55 to $18.51
• Volume: 2.73 million shs
• Average Volume: 1.31 million shs
• Market Capitalization: $1.56 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.00
• Consensus Rating: Buy

ARS Pharmaceuticals Stock Analysis - MarketRank™

ARS Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 339th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

ARS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ARS Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ARS Pharmaceuticals are expected to grow in the coming year, from ($0.55) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ARS Pharmaceuticals is -99.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ARS Pharmaceuticals is -99.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ARS Pharmaceuticals has a P/B Ratio of 6.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

31.29% of the float of ARS Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

ARS Pharmaceuticals has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.

Change versus previous month

Short interest in ARS Pharmaceuticals has recently decreased by 5.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ARS Pharmaceuticals does not currently pay a dividend.

Dividend Growth

ARS Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

31.29% of the float of ARS Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

ARS Pharmaceuticals has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.

Change versus previous month

Short interest in ARS Pharmaceuticals has recently decreased by 5.98%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.94

News Sentiment

ARS Pharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for ARS Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

8 people have searched for SPRY on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ARS Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,621,888.00 in company stock.

Percentage Held by Insiders

33.50% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

68.16% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SPRY Stock Analysis - Frequently Asked Questions

How have SPRY shares performed this year?

ARS Pharmaceuticals' stock was trading at $10.55 at the beginning of 2025. Since then, SPRY stock has increased by 50.8% and is now trading at $15.91.
View the best growth stocks for 2025 here.

How were ARS Pharmaceuticals' earnings last quarter?

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) issued its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.35) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.35). The business earned $7.97 million during the quarter, compared to the consensus estimate of $7.48 million. ARS Pharmaceuticals had a negative trailing twelve-month return on equity of 6.94% and a negative net margin of 16.11%.
Read the conference call transcript.

Who are ARS Pharmaceuticals' major shareholders?

Top institutional investors of ARS Pharmaceuticals include Alliancebernstein L.P. (3.99%), Vanguard Group Inc. (3.55%), Cormorant Asset Management LP (1.63%) and MPM Bioimpact LLC (1.34%). Insiders that own company stock include Ra Capital Management, LP, Richard E Lowenthal, Sarina Tanimoto, Laura Shawver, Justin Chakma, Alexander A Fitzpatrick, Eric Karas, Kathleen D Scott, Brian Dorsey, Peter A Thompson and Brent L Saunders.
View institutional ownership trends.

How do I buy shares of ARS Pharmaceuticals?

Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ARS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ARS Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 6/18/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SPRY
• CIK: 1671858
• Web: ars-pharma.com
• Phone: 206-456-2900
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $31.00
• High Stock Price Target: $40.00
• Low Stock Price Target: $27.00
• Potential Upside/Downside: +94.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $8 million
• Net Margins: -16.11%
• Pretax Margin: -15.82%
• Return on Equity: -6.94%
• Return on Assets: -5.60%

Debt

• Debt-to-Equity Ratio: 0.30
• Current Ratio: 11.00
• Quick Ratio: 10.74

Sales & Book Value

• Annual Sales: $89.15 million
• Price / Sales: 17.53
• Cash Flow: $0.01 per share
• Price / Cash Flow: 1,750.06
• Book Value: $2.64 per share
• Price / Book: 6.03

Miscellaneous

• Outstanding Shares: 98,210,000
• Free Float: 65,312,000
• Market Cap: $1.56 billion
• Optionable: Optionable
• Beta: 0.84